{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:47:58Z","timestamp":1789480078894,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,7]]},"DOI":"10.7759\/cureus.73205","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:30:15Z","timestamp":1730986215000},"source":"Crossref","is-referenced-by-count":10,"title":["The Efficacy of Eculizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study"],"prefix":"10.7759","author":[{"given":"Mitsuru","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu T","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, et al.. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007, 130:1224-34. 10.1093\/brain\/awm047","journal-title":"Brain"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai Y","year":"2021","unstructured":"Takai Y, Misu T, Suzuki H, et al.. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. 2021, 144:2401-15. 10.1093\/brain\/awab102","journal-title":"Brain"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock SJ","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al.. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019, 381:614-25. 10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda H","year":"2013","unstructured":"Kuroda H, Fujihara K, Takano R, et al.. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013, 254:178-82. 10.1016\/j.jneuroim.2012.09.002","journal-title":"J Neuroimmunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2016.05.012","article-title":"Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica","volume":"7","author":"Nishiyama S","year":"2016","unstructured":"Nishiyama S, Misu T, Nuriya M, et al.. Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica. Biochem Biophys Rep. 2016, 7:45-51. 10.1016\/j.bbrep.2016.05.012","journal-title":"Biochem Biophys Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090548","article-title":"Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders","volume":"14","author":"Miyamoto K","year":"2023","unstructured":"Miyamoto K, Minamino M, Kuwahara M, et al.. Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. Front Immunol. 2023, 14:1090548. 10.3389\/fimmu.2023.1090548","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Singh P","year":"2021","unstructured":"Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder. Front Neurol. 2021, 12:696387. 10.3389\/fneur.2021.696387","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton S","year":"2022","unstructured":"Chatterton S, Parratt JD, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol. 2022, 13:951423. 10.3389\/fneur.2022.951423","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15082\/jsnt.39.4_731","article-title":"Two cases of anti-aquaporin 4 antibody-positive neuromyelitis optica treated with eculizumab early after relapse","volume":"39","author":"Kaneko K","year":"2022","unstructured":"Kaneko K, Namioka Y, Ohyama A, et al.. Two cases of anti-aquaporin 4 antibody-positive neuromyelitis optica treated with eculizumab early after relapse. Neurol Therapeutics. 2022, 39:731-5. 10.15082\/jsnt.39.4_731","journal-title":"Neurol Therapeutics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06971-x","article-title":"Eculizumab for a catastrophic relapse in NMOSD: case report","volume":"45","author":"Gorriz D","year":"2024","unstructured":"Gorriz D, P\u00e9rez-Miralles FC, Quintanilla-Bord\u00e1s C, Alcal\u00e1 C, Frasquet M, Casanova B. Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci. 2024, 45:249-51. 10.1007\/s10072-023-06971-x","journal-title":"Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2024.100213","article-title":"Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: a case report","volume":"5","author":"Enriquez M","year":"2024","unstructured":"Enriquez M, Rosenthal S, McLendon LA, Bennett JL, Piquet AL, Kammeyer R. Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: a case report. Neuroimmunol Rep. 2024, 5:100213. 10.1016\/j.nerep.2024.100213","journal-title":"Neuroimmunol Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e05899","article-title":"CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder","volume":"7","author":"Namatame C","year":"2021","unstructured":"Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon. 2021, 7:e05899. 10.1016\/j.heliyon.2021.e05899","journal-title":"Heliyon"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00362","article-title":"Therapeutic inhibition of the complement system in diseases of the central nervous system","volume":"10","author":"Carpanini SM","year":"2019","unstructured":"Carpanini SM, Torvell M, Morgan BP. Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol. 2019, 10:362. 10.3389\/fimmu.2019.00362","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53661-5","article-title":"Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders","volume":"14","author":"Nishiyama S","year":"2024","unstructured":"Nishiyama S, Seok JM, Wright AE, et al.. Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders. Sci Rep. 2024, 14:3146. 10.1038\/s41598-024-53661-5","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310537-the-efficacy-of-eculizumab-in-the-acute-phase-of-neuromyelitis-optica-spectrum-disorder-a-case-series-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:30:17Z","timestamp":1730986217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310537-the-efficacy-of-eculizumab-in-the-acute-phase-of-neuromyelitis-optica-spectrum-disorder-a-case-series-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.73205","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}